179 related articles for article (PubMed ID: 31628842)
1. The Ulcerative Colitis Response Index for Detection of Mucosal Healing in Patients Treated With Anti-tumour Necrosis Factor.
de Bruyn M; Ringold R; Martens E; Ferrante M; Van Assche G; Opdenakker G; Dukler A; Vermeire S
J Crohns Colitis; 2020 Feb; 14(2):176-184. PubMed ID: 31628842
[TBL] [Abstract][Full Text] [Related]
2. Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn's Disease.
de Bruyn M; Arijs I; De Hertogh G; Ferrante M; Van Assche G; Rutgeerts P; Vermeire S; Opdenakker G
J Crohns Colitis; 2015 Dec; 9(12):1079-87. PubMed ID: 26351381
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate serum marker of mucosal healing in ulcerative colitis.
de Bruyn M; Arijs I; Wollants WJ; Machiels K; Van Steen K; Van Assche G; Ferrante M; Rutgeerts P; Vermeire S; Opdenakker G
Inflamm Bowel Dis; 2014 Jul; 20(7):1198-207. PubMed ID: 24871805
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.
Paul S; Del Tedesco E; Marotte H; Rinaudo-Gaujous M; Moreau A; Phelip JM; Genin C; Peyrin-Biroulet L; Roblin X
Inflamm Bowel Dis; 2013 Nov; 19(12):2568-76. PubMed ID: 24013361
[TBL] [Abstract][Full Text] [Related]
5. INFLIXIMAB AND ADALIMUMAB SERUM TROUGH CONCENTRATIONS THRESHOLD ASSOCIATED WITH DEEP REMISSION IN INFLAMMATORY BOWEL DISEASE.
Pascual-Marmaneu Ó; Belles-Medall MD; Ferrando-Piqueres R; Almela-Notari P; Mendoza-Aguilera M; Álvarez-Martín T
Farm Hosp; 2021 Aug; 45(5):225-233. PubMed ID: 34806581
[TBL] [Abstract][Full Text] [Related]
6. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.
Hassan EA; Ramadan HK; Ismael AA; Mohamed KF; El-Attar MM; Alhelali I
Saudi J Gastroenterol; 2017; 23(4):238-245. PubMed ID: 28721978
[TBL] [Abstract][Full Text] [Related]
7. Histological healing after infliximab induction therapy in children with ulcerative colitis.
Wiernicka A; Szymanska S; Cielecka-Kuszyk J; Dadalski M; Kierkus J
World J Gastroenterol; 2015 Oct; 21(37):10654-61. PubMed ID: 26457025
[TBL] [Abstract][Full Text] [Related]
8. Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis.
Olsen T; Rismo R; Gundersen MD; Paulssen EJ; Johnsen K; Kvamme JM; Goll R; Florholmen J
Cytokine; 2016 Mar; 79():90-5. PubMed ID: 26775117
[TBL] [Abstract][Full Text] [Related]
9. Correlation Between Anti-TNF Serum Levels and Endoscopic Inflammation in Inflammatory Bowel Disease Patients.
Chaparro M; Barreiro-de Acosta M; Echarri A; Almendros R; Barrio J; Llao J; Gomollón F; Vera M; Cabriada JL; Guardiola J; Guerra I; Beltrán B; Roncero O; Busquets D; Taxonera C; Calvet X; Ferreiro-Iglesias R; Ollero Pena V; Bernardo D; Donday MG; Garre A; Godino A; Díaz A; Gisbert JP
Dig Dis Sci; 2019 Mar; 64(3):846-854. PubMed ID: 30426297
[TBL] [Abstract][Full Text] [Related]
10. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study.
Iwasa R; Yamada A; Sono K; Furukawa R; Takeuchi K; Suzuki Y
BMC Gastroenterol; 2015 Aug; 15():103. PubMed ID: 26271624
[TBL] [Abstract][Full Text] [Related]
11. [Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission].
Muñoz Villafranca C; Bravo Rodríguez MT; Ortiz de Zárate J; Arreba González P; García Kamiruaga I; Heras Martín JI; Cabezudo Gil P; Orive Cura V
Gastroenterol Hepatol; 2016; 39(7):442-8. PubMed ID: 26948837
[TBL] [Abstract][Full Text] [Related]
12. Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis.
Papamichael K; Baert F; Tops S; Assche GV; Rutgeerts P; Vermeire S; Gils A; Ferrante M
J Crohns Colitis; 2017 Jan; 11(1):53-59. PubMed ID: 27402915
[TBL] [Abstract][Full Text] [Related]
13. [The diagnostic and evaluation value of plasma interleukin 9 in the mucosal healing in patients with inflammatory bowel disease treated with biological agents].
Ye YL; Hu T; Xu LJ; Zhang LP; Yin J; Yu Q; Pang Z
Zhonghua Yi Xue Za Zhi; 2023 May; 103(19):1483-1489. PubMed ID: 37198111
[No Abstract] [Full Text] [Related]
14. Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort.
Bálint A; Rutka M; Kolar M; Bortlik M; Duricova D; Hruba V; Lukas M; Mitrova K; Malickova K; Lukas M; Szepes Z; Nagy F; Palatka K; Lovas S; Végh Z; Kürti Z; Csontos Á; Miheller P; Nyári T; Bor R; Milassin Á; Fábián A; Szántó K; Lakatos PL; Molnár T; Farkas K
Expert Opin Biol Ther; 2018 Nov; 18(11):1181-1187. PubMed ID: 30277084
[TBL] [Abstract][Full Text] [Related]
15. Endoscopic and clinical variables that predict sustained remission in children with ulcerative colitis treated with infliximab.
Turner D; Griffiths AM; Veerman G; Johanns J; Damaraju L; Blank M; Hyams J
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1460-5. PubMed ID: 23672831
[TBL] [Abstract][Full Text] [Related]
16. Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis.
Fernández-Blanco JI; Fernández-Díaz G; Cara C; Vera MI; Olivares D; Taxonera C
Dig Dis Sci; 2018 Mar; 63(3):731-737. PubMed ID: 29372480
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.
Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
Aliment Pharmacol Ther; 2016 May; 43(9):994-1003. PubMed ID: 26991059
[TBL] [Abstract][Full Text] [Related]
18. Accuracies of fecal calprotectin, lactoferrin, M2-pyruvate kinase, neopterin and zonulin to predict the response to infliximab in ulcerative colitis.
Frin AC; Filippi J; Boschetti G; Flourie B; Drai J; Ferrari P; Hebuterne X; Nancey S
Dig Liver Dis; 2017 Jan; 49(1):11-16. PubMed ID: 27693318
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis.
Farkas K; Rutka M; Golovics PA; Végh Z; Lovász BD; Nyári T; Gecse KB; Kolar M; Bortlik M; Duricova D; Machkova N; Hruba V; Lukas M; Mitrova K; Malickova K; Bálint A; Nagy F; Bor R; Milassin Á; Szepes Z; Palatka K; Lakatos PL; Lukas M; Molnár T
J Crohns Colitis; 2016 Nov; 10(11):1273-1278. PubMed ID: 27106537
[TBL] [Abstract][Full Text] [Related]
20. Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition.
Magnusson MK; Strid H; Sapnara M; Lasson A; Bajor A; Ung KA; Öhman L
J Crohns Colitis; 2016 Aug; 10(8):943-52. PubMed ID: 26896085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
